» Articles » PMID: 35147767

Target and Non-target Vessel Related Events at 10 Years Post Percutaneous Coronary Intervention

Abstract

Aims: To define the incidence of events related to the stented vessel (target vessel related events: TVRE) and events related to non-stented vessels (non-target vessel related events: NTVRE) through to 10-year follow-up in patients post-PCI with newer generation drug eluting stents (DES).

Methods And Results: The current study is a post-hoc analysis of patient level data from two randomised controlled trials in Germany. Patients older than 18 years with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in the native coronary vessels were considered eligible. The endpoints of interest were TVRE (a composite of first target vessel myocardial infarction or target vessel revascularization) and NTVRE (a composite of first non-target vessel MI or non-target vessel revascularization) through to 10 years post PCI. We included 4953 patients in this analysis. Through to 10-years post-PCI, TVRE occurred in 1238 of 4953 patients (cumulative incidence: 25.8%) and NTVRE occurred in 1442 of 4953 patients (cumulative incidence: 30.3%). The majority of TVRE and NTVRE were revascularization events. From 0 to 1 years, the cumulative incidence of TVRE was 15.9% and of NTVRE was 12.3%. From 1 to 10 years, the cumulative incidences of TVRE and NTVRE were 11.2% and 22.4%, respectively.

Conclusion: At 10-year post-PCI with new generation drug eluting stents, events related to remote vessel disease progression account for a higher proportion of events than events related to the stented vessel.

Trial Registration: ISAR TEST 4 ClinicalTrials.gov Identifier: NCT00598676. ISAR TEST 5 ClinicalTrials.gov Identifier: NCT00598533.

Citing Articles

Comparison of the Effects of Indobufen and Aspirin in Older Patients with Coronary Artery Disease After Coronary Drug-Eluting Stent Implantation: A Prospective Randomized Single-Center Study.

Wu Y, Gao Z, Jin Q, Zheng J, Xu H, Tu X Clin Appl Thromb Hemost. 2024; 30:10760296241309633.

PMID: 39686662 PMC: 11788808. DOI: 10.1177/10760296241309633.


Unraveling the rapid progression of non-target lesions: risk factors and the therapeutic potential of PCSK9 inhibitors in post-PCI patients.

Mei J, Fu X, Liu Z, Zhang L, Geng Z, Xie W BMC Cardiovasc Disord. 2024; 24(1):499.

PMID: 39294556 PMC: 11409538. DOI: 10.1186/s12872-024-04186-2.


The molecular genetics of PI3K/PTEN/AKT/mTOR pathway in the malformations of cortical development.

Ma Q, Chen G, Li Y, Guo Z, Zhang X Genes Dis. 2024; 11(5):101021.

PMID: 39006182 PMC: 11245990. DOI: 10.1016/j.gendis.2023.04.041.


Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel.

Aytekin A, Scalamogna M, Coughlan J, Lahu S, Ndrepepa G, Menichelli M Clin Res Cardiol. 2024; 113(7):1060-1069.

PMID: 38740722 PMC: 11219404. DOI: 10.1007/s00392-024-02454-x.


Perivascular fat attenuation index value and plaque volume increased in non-target lesions of coronary arteries after stenting.

Zuo L, Tian Z, Zhou B, Hou M, Chen Y, Han P Eur Radiol. 2023; 34(7):4233-4242.

PMID: 38057594 DOI: 10.1007/s00330-023-10468-8.

References
1.
Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K . Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. Circulation. 2018; 139(3):325-333. DOI: 10.1161/CIRCULATIONAHA.118.038065. View

2.
Mitchell J, Brown D . Harmonizing the Paradigm With the Data in Stable Coronary Artery Disease: A Review and Viewpoint. J Am Heart Assoc. 2017; 6(11). PMC: 5721779. DOI: 10.1161/JAHA.117.007006. View

3.
Joner M, Finn A, Farb A, Mont E, Kolodgie F, Ladich E . Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48(1):193-202. DOI: 10.1016/j.jacc.2006.03.042. View

4.
Abdel-Wahab M, Neumann F, Serruys P, Silber S, Leon M, Mauri L . Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program. EuroIntervention. 2015; 12(4):465-72. DOI: 10.4244/EIJY15M07_07. View

5.
Spitaleri G, Moscarella E, Brugaletta S, Pernigotti A, Ortega-Paz L, Gomez-Lara J . Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. EuroIntervention. 2017; 13(16):1939-1945. DOI: 10.4244/EIJ-D-17-00608. View